Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 32, Issue 17, 2019, Pages 2797-2804

  Holm, Charlotte ^a,b   Thomsen, Lars L ^c   Langhoff Roos, Jens ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c Pharmacosmos AS   (Denmark)

Author keywords

Anemia; intravenous iron; iron deficiency; postpartum depression; postpartum hemorrhage

Indexed keywords

IRON ISOMALTOSE; DISACCHARIDE; FERRIC ION;

ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; EDINBURGH POSTNATAL DEPRESSION SCALE; FATIGUE; FEMALE; FEVER; HEMATOLOGICAL PARAMETERS; HEMORRHOID; HUMAN; INJECTION SITE DISCOLORATION; INJECTION SITE IRRITATION; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MULTIDIMENSIONAL FATIGUE INVENTORY; MYALGIA; OPEN STUDY; PHLEBITIS; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE DRUG DOSE; TREATMENT OUTCOME; BLOOD; INTRAVENOUS DRUG ADMINISTRATION; POSTNATAL DEPRESSION; PREGNANCY; PSYCHOLOGY; QUESTIONNAIRE;

ADULT; DEPRESSION, POSTPARTUM; DISACCHARIDES; FATIGUE; FEMALE; FERRIC COMPOUNDS; HUMANS; INFUSIONS, INTRAVENOUS; POSTPARTUM HEMORRHAGE; PREGNANCY; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 85044230148     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767058.2018.1449205     Document Type: Article

References (27)

1. WHO Global Database on Anaemia. Worldwide prevalence of anaemia 1993–2005. Atlanta: Center for Disease Control and Prevention; 2008.
2. World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage; 2012.
3. Sundhedsstyrelsen [Internet]. National klinisk retningslinje om Indikation for transfusion Med blodkomponenter; [cited 2017 Dec 21]. Available from: https://sundhedsstyrelsen.dk/da/udgivelser/2014/∼/media/EEA1EA90C15E4A97B9E786D2850B3664.ashx
4. Goldberg ND., Iron deficiency anemia in patients with inflammatory bowel disease. Clin Exp Gastroenterol. 2013;6:61–70.
5. KDIGO clinical practice guideline for anemia in chronic kidney disease [Internet]; 2012. Vol. 2; [cited 2017 Dec 21]. Available from: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-Anemia%20GL.pdf
6. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211–222.
7. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13:1545–1553.
8. Hildebrandt PR, Bruun NE, Nielsen OW, et al. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study. TATM. 2010;11:131–137.
9. Wikström B, Bhandari S, Barany P, et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol. 2011;24:589–596.
10. Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol. 2013;108:1877–1888.
11. Reinisch W, Altorjay I, Zsigmond F, et al. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scand J Gastroenterol. 2015;50:1226–1233.
12. ®) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant. 2015;30:1577–1589.
13. Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant. 2016;31:646–655.
14. Birgegård G, Henry D, Glaspy J, et al. A randomized, noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy: The PROFOUND Trial. Pharmacotherapy. 2016;36:402–414.
15. Dahlerup JF, Jacobsen BA, van der Woude J, et al. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand J Gastroenterol. 2016;51:1332–1338.
16. Derman R, Roman E, Modiano MR, et al. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol. 2017;92:286–291.
17. ®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox Sang. 2015;109:257–266.
18. Holm C, Thomsen LL, Norgaard A, et al. Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: a randomized controlled trial. Vox Sang. 2017;112:219–228.
19. Holm C, Thomsen LL, Norgaard A, et al. Single-dose intravenous iron infusion versus red blood cell transfusion for the treatment of severe postpartum anaemia: a randomized controlled pilot study. Vox Sang. 2017;112:122–131.
20. Holm C, Thomsen LL, Norgaard A, et al. Intravenous iron isomaltoside 1000 administered by high single-dose infusions or standard medical care for the treatment of fatigue in women after postpartum haemorrhage: study protocol for a randomised controlled trial. Trials. 2015;16:5.
21. Jansen AJ, Essink-Bot ML, Duvekot JJ, et al. Psychometric evaluation of health-related quality of life measures in women after different types of delivery. J Psychosom Res. 2007;63:275–281.
22. Gibson J, McKenzie-McHarg K, Shakespeare J, et al. A systematic review of studies validating the Edinburgh Postnatal Depression Scale in antepartum and postpartum women. Acta Psychiatr Scand. 2009;119:350–364.
23. Sheikh M, Hantoushzadeh S, Shariat M, et al. The efficacy of early iron supplementation on postpartum depression, a randomized double-blind placebo-controlled trial. Eur J Nutr. 2017;56:901–908.
24. Holm C, Thomsen LL, Norgaard A, et al. Iron concentration in breast milk normalised within one week of a single high-dose infusion of iron isomaltoside in randomised controlled trial. Acta Paediatr. 2017;106:256–260.
25. Kavle JA, Stoltzfus RJ, Witter F, et al. Association between anaemia during pregnancy and blood loss at and after delivery among women with vaginal births in Pemba Island, Zanzibar, Tanzania. J Health Popul Nutr. 2008;26:232–240.
26. Jaleel R, Khan A., Post-partum haemorrhage–a risk factor analysis. Mymensingh Med J. 2010;19:282–289.
27. Frass KA., Postpartum hemorrhage is related to the hemoglobin levels at labor: observational study. Alex J Med. 2015;51:333–337.